--- title: Are you really moving towards a GLocal Regulatory approach? description: Project Orbis and other collaborative projects are shaping the future of Regulatory Affairs, helping patients by getting products to market in shorter times. image: https://blog.pqegroup.com/hubfs/GLocal%20Regulatory%20approach_banner%20insight-1.jpg --- [![Logo PQE Group - azzurro - 2024](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20PQE%20Group%20-%20azzurro%20-%202024.png?width=2000&height=721&name=Logo%20PQE%20Group%20-%20azzurro%20-%202024.png "Logo PQE Group - azzurro - 2024")](https://www2.pqegroup.com) - [Home](https://www2.pqegroup.com/) - [Industry](https://www2.pqegroup.com/industry/) - [Pharma & API](https://www2.pqegroup.com/pharma-api/) - [Medical Device](https://www2.pqegroup.com/medical-device/) - [Biotech](https://www2.pqegroup.com/biotech/) - [Startup](https://www2.pqegroup.com/startup/) - [Veterinary](https://www2.pqegroup.com/veterinary/) - [Services](https://www2.pqegroup.com/services/) - [Data Integrity](https://www2.pqegroup.com/data-integrity/) - [Digital Governance](https://www2.pqegroup.com/digital-governance/) - [Engineering](https://www2.pqegroup.com/engineering/) - [Commissioning, Qualification and Validation (CQV)](https://www2.pqegroup.com/commissioning-qualification-validation/) - [Quality Compliance](https://www2.pqegroup.com/quality-compliance/) - [Laboratory Excellence](https://www2.pqegroup.com/laboratory-excellence/) - [Regulatory Affairs](https://www2.pqegroup.com/regulatory-affairs/) - [Audits](https://www2.pqegroup.com/audits/) - [Training](https://www2.pqegroup.com/training/) - [Clinical Research](https://www2.pqegroup.com/clinical-research-services/) - [Pharmacovigilance](https://www2.pqegroup.com/pharmacovigilance/) - About - [About Us](https://www2.pqegroup.com/about/) - [ESG](https://www2.pqegroup.com/about/csr/) - [Women in STEM](https://www2.pqegroup.com/about/women-in-stem/) - Resources - [News & Press](https://www2.pqegroup.com/news/) - [Webinars](https://www2.pqegroup.com/webinars/) - [Blog](https://blog.pqegroup.com/) - [Careers](https://www2.pqegroup.com/careers/) - [Contact Us](https://www2.pqegroup.com/contact-us/) ![Concetta Aulicino](https://blog.pqegroup.com/hubfs/Concetta_Aulicino-1.jpg) Concetta Aulicino Regulatory Affairs Executive Consultant @PQE Group # **Are you really moving towards a GLocal Regulatory approach?** [Regulatory Affairs](https://blog.pqegroup.com/tag/regulatory-affairs) ## Thinking Globally and Acting Locally, a new approach to RA  With the Covid-19 Pandemic, the world has experienced a massive change in many of its aspects; One of them is the renewed necessity to bring products on the market in a faster way than before.  To respond to such challenge, Regulatory Authorities have developed collaborative procedures to guarantee faster access to products.            ## Project Orbis  shaping the future of RA According to IQVIA analysis on April 2022 “Over 250 new drugs are expected to launch within the next five years and contribute over $100Bn in new spending. Immunology, oncology and neurology will drive the most growth in spending during the forecast period, and next generation biotherapeutics may reach as much as $20Bn in annual sales by 2026, though significant scientific and commercial uncertainty exists in this fast-evolving area”. This outlook is easily predictable considering the latest data published by FDA. Indeed, FDA approved 50 new drugs in 2021, Oncology approvals as NMEs/BLA were 16, this means that more than 30% of new drugs will be for the treatment of cancer. Among them, 8 NMEs were selected and approved under Project Orbis launched by FDA on May, 2019. If this trend is confirmed, in the next five years, 50% of the new anticancer drugs will be enrolled under Project Orbis to be concurrently reviewed by FDA and one or more Regulatory Health Authorities (RHAs) Participating Orbis Partners (POP). So far, TGA ANVISA Health Canada Israel Ministry of Health, Singapore Health Sciences Authority, Swissmedic and MHRA are involved. The requirement for the preparation of Module 1 are country specific and a local regulatory knowledge is helpful to speed up the review time. Each country remains fully independent on their final regulatory decision. A global international cooperation among like-minded medium-sized regulatory authorities to support the industry through the development phases of a drugs as well as to speed up the review phase of a Marketing Authorisation was built in the late 2007 among Australia, Canada, Singapore and Switzerland (ACSS). With the addition of the United Kingdom’s Medicines and Healthcare Product Regulatory Agency, in October 2020, the ACSS changed its name to Access Consortium. Unlike the Project Orbis, the submission under the Access Consortium is initiated by sponsors filing an “Expression of Interest” (EOI) application form and it is not restricted to oncology medicines. Access Consortium initiatives include several working groups with various objective and projects. The main groups are: - Generic Medicines Working Group (GMWG) involved in a new innovative authorization procedure for “known active substance without innovation” - New Active Substance (NAS) Working Group suitable for companies that submit authorization application for a new chemical or biological active substance or for an additional indication simultaneously to at least two members of the Access Consortium. Technical reviews are divided between the Authorities and subsequently shared while the administrative country specific information collected in the module 1 will be independently reviewed by the single Authority. Upon completion of the review, each agency will issue independent decisions regarding the approval of the medicines. - Biosimilar Working Group (BSWG) What about EMA? **EMA is leading a pilot project “OPEN”** in collaboration with HC, PMDA, Swissmedic, TGA and the WHO. The objective of the OPEN pilot project is to allow active international participation in scientific evaluation, in the context of COVID-19 by regulatory authorities with confidentiality arrangements.     ## A Glocal Approach The above listed international projects showed a **new collaborative approach** and the term “Glocal” wants to highlight the importance of the coordination among local resources involved in the regulatory activities and a global view of the pathway to get a simultaneous approval in multiple markets. The Glocal approach starts from the local to get to the global. The efforts towards convergence is a challenge for the RHA as well as for the Pharmaceutical companies. Less bureaucracy, global flexibility and a timely interactive communication with all Authorities involved in the multiple markets projects are the levers to streamline the medicines regulatory framework providing a faster patient access to the care and less cost and time to develop a medicinal product.   ![GLocal Regulatory approach_banner insight](https://blog.pqegroup.com/hubfs/GLocal%20Regulatory%20approach_banner%20insight.jpg) ## Want to know more, or need support? PQE Supports Marketing Authorization Holders, Manufacturers of API and Manufacturers of Finished products. Our experts have significant expertise in Regulatory Intelligence to make you aware of regulatory requirements applicable to Clients’portfolio and PQE could offer a CMC Regulatory support at every stage of development, registration and life cycle management. [Connect with us](https://www2.pqegroup.com/contact-us/) [Visit our Regulatory Affairs page](https://www2.pqegroup.com/regulatory-affairs/) #### More on this topic [Regulatory Affairs ![eCTD as your strategic asset: Rethinking eCTD in Modern Regulatory Affairs](https://blog.pqegroup.com/hubfs/eCTD%20Regulatory%20Affairs_Blog.webp)](https://blog.pqegroup.com/regulatory-affairs/ectd-as-your-strategic-asset-rethinking-ectd-in-modern-regulatory-affairs) 06 Jul 2026 ## [eCTD as your strategic asset: Rethinking eCTD in Modern Regulatory Affairs Transform eCTD from a compliance requirement into a strategic asset. Learn how regulatory teams improve efficiency, reduce risk, and accelerate submissions](https://blog.pqegroup.com/regulatory-affairs/ectd-as-your-strategic-asset-rethinking-ectd-in-modern-regulatory-affairs) [Regulatory Affairs ![USP <665>/<1665> Compliance: Risk Assessment for Biotech & API Manufacturing](https://blog.pqegroup.com/hubfs/BANNER-USP%20Regulation%20-%20Plastic%20Contamination%20Risks%20and%20Single-Use%20Systems-1.jpg)](https://blog.pqegroup.com/regulatory-affairs/usp-665-1665-compliance-risk-assessment-for-biotech-and-api-manufacturing) 29 Apr 2026 ## [USP <665>/<1665> Compliance: Risk Assessment for Biotech & API Manufacturing USP <665> goes live in 2026. Are your polymer components compliant? Learn why early risk assessment is the key—and how to prepare.](https://blog.pqegroup.com/regulatory-affairs/usp-665-1665-compliance-risk-assessment-for-biotech-and-api-manufacturing) [Regulatory Affairs ![ICH M14: A Harmonized Approach to Non Interventional Studies](https://blog.pqegroup.com/hubfs/ICH%20M14_Blog_1-1.jpg)](https://blog.pqegroup.com/regulatory-affairs/a-harmonized-approach-to-non-interventional-studies) 20 Mar 2026 ## [ICH M14: A Harmonized Approach to Non Interventional Studies ICH M14 provides a global framework for non‑interventional studies using real‑world data, enhancing transparency, consistency, and methodological rigor.](https://blog.pqegroup.com/regulatory-affairs/a-harmonized-approach-to-non-interventional-studies) ![new PQE logo white tagline](https://blog.pqegroup.com/hubfs/new%20PQE%20logo%20white%20tagline.png) ISO 9001 Certified compliance services provider since 1998.   ![Logo ISO 9001](https://blog.pqegroup.com/hs-fs/hubfs/Logo%20ISO%209001.png?width=125&name=Logo%20ISO%209001.png)   - Discover PQE - [Work with PQE](https://www2.pqegroup.com/careers/) - [Locations](https://www2.pqegroup.com/contact-us/#locations) - [About](https://www2.pqegroup.com/about/) - [Blog](https://blog.pqegroup.com/) - Useful Links - [Privacy Notice](https://www2.pqegroup.com/privacy-notice/) - [Cookie Policy](https://www2.pqegroup.com/cookie-policy/) - [Model of Organization](https://www2.pqegroup.com/model-of-organization/) - [Ethical Code](https://www2.pqegroup.com/ethical-code/) English - [English](https://blog.pqegroup.com/ra-phv/moving-towards-glocal-regulatory-approach) - [Português - Brasil](https://blog.pqegroup.com/pt-br/assuntos-regulatorios-farmacovigilancia/caminhando-para-uma-abordagem-regulatoria-glocal) CHANGE LANGUAGE Copyright **2024** | Proudly powered by **PQE Group Creative Team** [LinkedIn](https://www.linkedin.com/company/pqe-group) [![twitter](https://blog.pqegroup.com/hubfs/twitter-w.png) Twitter](https://twitter.com/PQEGroup) [Facebook](https://www.facebook.com/PQEGroup/) [Instagram](https://www.instagram.com/lifeatpqe) [YouTube](https://www.youtube.com/c/PQEGroup) [Xing](https://www.xing.com/pages/pqegroup)